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pilepsy is one of the most prevalent neurological diseases, affecting an estimated 3 million individuals in the United States and 50 million people world wide. 1 This review article outlines the breadth of epilepsy treatments currently available and under development. The mechanisms of actions, indications, and adverse effects of AEDs are outlined, along with providing guidelines as to how to choose a specific AED for a patient. Nonpharmacological treatments, including dietary and device therapies, are presented. Finally, the role of surgery in treating intractable epilepsy is discussed.
ANTIEPILEPTIC DRUGS
In contrast to the treatment of epilepsy 30 years ago, there are now more than 20 approved AEDs available. This allows better selection of AEDs based on seizure type and adverse effect profile, but can be daunting when it comes to choosing where to start with AED selection. Understanding the seizure type, patient comorbidities, and ease of dosing, along with consideration of the mechanism of action, are all important in guiding AED selection.
The primary aim of AEDs is to inhibit seizure propagation by either increasing neuronal inhibitory signaling or decreasing excitatory signaling. Multiple targets are used to exert this effect (Table 1) .
g-Aminobutyric acid (GABA) is a neurotransmitter with an important role in neuronal inhibition. Increased presence of GABA in the synapse increases inhibition and increases the seizure threshold. Two AEDs were specifically designed to increase GABA: tiagabine, which inhibits the GABA transporter on the presynaptic neuron, inhibiting GABA reuptake; and vigabatrin, which blocks GABA transaminase, preventing breakdown of GABA. 3 Valproic acid also likely exerts its effect partially by increasing availability of GABA. 4 Increased activation of GABA receptors inhibits postsynaptic signal propagation. Both benzodiazepines and barbiturates exert their action on synaptic GABA A receptors, causing inhibition of signal transmission when activated. Benzodiazepines bind to a specific site on the GABA A receptor, causing the channel to open more frequently, increasing the inhibitory signal. Barbiturates activate GABA A channels when they bind, causing the channel to have a long duration of opening. 4 Neuroactive steroids modulate synaptic and extrasynaptic GABA A channels, increasing neuronal inhibition and reducing seizure propagation. Multiple neurosteroids are currently in clinical trials for the treatment of epilepsy. Ganaxolone, an analogue of allopregnanolone, has shown benefit for focal epilepsy and infantile spasms in phase 2 trials. 5 It recently received orphan drug status in the treatment of epilepsy-associated syndrome because of sequence variations of the protocadherin 19 (PCDH19) gene. An intravenous form of allopregnanolone, SAGE-547, may be of benefit in super-refractory status epilepticus and is now entering phase 3 trials. Allopregnanolone has an advantage over benzodiazepines and barbiturates in refractory status epilepticus, in that it acts on extra synaptic GABA A MANAGEMENT OF ADULT ONSET SEIZURES receptors. As opposed to synaptic GABA A receptors that older AEDs work on, extrasynaptic GABA A receptors are not internalized with continuous seizure activity and remain an available target. 6 Glutamate is the primary excitatory neurotransmitter in the central nervous system, which acts on multiple ionotropic and metabotropic postsynaptic receptors. The ionotropic types are a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, N-methyl-D-aspartate (NMDA), and kainate receptors, which, when activated, allow an influx of Na þ and Ca 2þ , resulting in depolarization of the postsynaptic neuron. Metabotropic receptors are also contained in the membranes, but rather than acting as ion channels, their activation leads to a series of actions, ultimately modifying the target protein. Felbamate inhibits NMDA channels, whereas topiramate and perampanel inhibit a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid channels, resulting in a decrease in neuroexcitation. 3, 4, 7 These pathways are an attractive target for prolonged seizure activity, as synaptic GABA receptors are internalized and there is increased expression of NMDA receptors. Ketamine, a noncompetitive NMDA receptor antagonist, has been shown to have efficacy in the treatment of refractory status epilepticus. 8 After synaptic depolarization, voltage-gated sodium channels propagate action potentials as the influx of sodium depolarizes the membrane. Blocking of the sodium channels instead results in hyperpolarization, reducing neuronal firing and preventing seizure propagation. Multiple first-line AEDs exert their effect through blocking voltage-gated sodium channels, including phenytoin, carbamazepine, lamotrigine, lacosamide, and rufinamide. 4, 7 These "sodium channel blockers" preferentially inhibit action potentials occurring at high frequencies, which are characteristic of seizure discharges, as opposed to normal neuronal activity. 9 Levetiracetam, and its structural analogue brivaracetam, exerts its effect through a novel mechanism. These AEDs bind to synaptic vesicle glycoprotein 2A, which is thought to play a role in synaptic vesicle exocytosis and neurotransmitter release. 10 However, the specifics of how synaptic vesicle glycoprotein 2A leads to an antiseizure effect are not known and are under investigation.
Ezogabine was approved for adjunctive therapy for focal epilepsy in 2011 and was first in its class as a potassium channel modulator. Activation of the ion channels KCNQ is believed to decrease neuronal excitability. 11 Increasing numbers of anecdotal reports and media attention have led to recent trials using cannabis as a treatment of epilepsy. The endocannabinoid system involves cannabinoid receptor types 1 and 2 that are distributed through the brain, immune system, peripheral nervous system, and gastrointestinal tract. Cannabinoid receptor type 1 receptors are thought to play a role in food intake regulation, stress and reward responses, gastrointestinal tract regulation, and cardiovascular activity. Cannabinoid receptor type 2 receptors may be involved in immune regulation, addictive behavior, and neurodegeneration. The precise antiepileptic role of the endocannabinoid system has not been fully elucidated, and cannabidiol (CBD) only has a low affinity for cannabinoid receptor types 1 and 2. Cannabidiol has been shown to have an antiepileptic effect in multiple animal models. Proposed mechanisms include action on serotonergic receptors, NMDA or GABA receptors, regulation of Ca 2þ flow, or enhancement of adenosine signaling. 12 The role of CBD in the treatment of epilepsy has not yet been determined. At this time, larger, prospective, placebo controlled trials are needed in a wider range of patients to determine the efficacy of CBD in the treatment of epilepsy.
Although it is important to understand the underlying mechanisms of actions of AEDs, for the purposes of clinical practice, it is imperative to consider seizure types, comorbid conditions, and common adverse effects to tailor drug selection to an individual patient.
Selection of an AED requires determination of the seizure type being treated (Table 2) . Broad spectrum AEDs work on multiple seizure types and are effective for focal and generalized onset seizures, whereas narrow spectrum AEDs may only be effective for 1 seizure type, such as carbamazepine for focal seizures and ethosuximide for absence seizures. Choosing a narrow spectrum AED, such as gabapentin or carbamazepine, in a patient with primary generalized epilepsy has the potential to worsen seizure control. There are limited data on comparative efficacy of AEDs for specific seizure types. For an AED to be approved by the Food and Drug Administration (FDA), it needs to be studied in randomized, double-blind, placebo-controlled trials, which do not allow a direct comparison of AEDs. Large comparison trials are logistically difficult and expensive, but have successfully been completed on a few occasions. The SANAD trial enrolled 1721 patients and compared carbamazepine, gabapentin, lamotrigine, topiramate, and oxcarbazepine for focal epilepsy and valproate, lamotrigine, and topiramate for generalized or unclassified epilepsy. In patients with focal epilepsy, lamotrigine was more effective than carbamazepine, with time to treatment failure as the primary outcome. In generalized or unclassified epilepsy, valproate was better tolerated than topiramate and more effective than lamotrigine. 13, 14 Each AED carries a risk of potential adverse effects, and understanding common adverse effects assists in choosing the appropriate AED for an individual patient (Table 3) . Most AEDs go through hepatic metabolism, which carries a higher risk of medication interactions. Renally excreted AEDs (Table 4 ) minimize the risk of medication interactions. Enzyme inducers, in particular phenytoin, phenobarbital, and carbamazepine, increase the risk of osteoporosis with long-term use.
Sodium channel blockers, phenytoin, carbamazepine, oxcarbazepine, lamotrigine, and lacosamide, all are commonly associated with double vision and gait imbalance. These adverse effects may be enhanced with polypharmacy including more than 1 AED in this class. These medications also have the potential to affect cardiac conduction. Carbamazepine, oxcarbazepine, and eslicarbazepine all can lead to hyponatremia.
Valproate, though effective for generalized epilepsy, does carry multiple potential risks. Common adverse effects include weight gain, sedation, and tremor. Serious potential adverse events are liver failure and pancreatitis. For women of childbearing potential, valproate should be avoided if possible because of a marked increased risk of major congenital malformation, compared with other AEDs, and a negative effect on IQ of children exposed in utero.
Levetiracetam has the advantage of being entirely renally excreted, eliminating medication interactions. The most common adverse effect is an adverse effect on mood: depression, anxiety, or irritability. Patients may also have fatigue when initiating this medication. These adverse effects may improve over the first several weeks on the medication, but not in all cases. Brivaracetam, an analogue of levetiracetam, may carry a lower risk of adverse mood effects. Zonisamide and topiramate both carry risks of metabolic acidosis, kidney stones, and weight loss. Zonisamide can also be associated with fatigue, whereas cognitive decline is a common doserelated adverse effect of topiramate. Topiramate carries an increased risk of major congenital malformations. Gabapentin and pregabalin may both be associated with weight gain, lower extremity edema, gait imbalance, and dizziness.
Novel AEDs still carry risks of specific adverse effects. In clinical trials, ezogabine was recognized as carrying a risk of QT prolongation and urinary retention. Postmarketing data revealed a risk of skin discoloration and retinal abnormalities, which could be permanent. The FDA released a safety alert about these adverse events. In 2016, the manufacturer decided to discontinue production of ezogabine because of low usage of the medication. Clobazam is associated with fatigue and depression. Perampanel was shown to have adverse mood effects in phase 3 clinical trials, with endorsement of both suicidal and homicidal ideations.
Generic AEDs are often preferred by pharmacies and patients because of lower cost and wider availability; however, there can be anxiety with regard to transitioning from brand 15, 16 did not report increased seizures when patients already on generic AEDs changed manufacturers. These data indicate that patients can safely be transitioned to generic AEDs when needed, without adverse effects on seizure control.
TREATMENT IN SPECIAL POPULATIONS Pregnant Women
For women with epilepsy, continuation of AEDs during pregnancy is imperative for the health of both the mother and the baby. A meta-analysis 17 found that for women with epilepsy on an AED, the risk of major malformations is twice that of women with untreated epilepsy or in control populations. However, each individual AED carries a separate risk of congenital malformations.
Carbamazepine, lamotrigine, phenytoin, and levetiracetam are widely used, and all have a relatively lower risk, though still present, of malformations when a woman is exposed during the first trimester of pregnancy. The rates of major congenital malformations are between 2% and 2.5%, with narrow CIs. Valproate and phenobarbital carry increased risks, between 6% and 9%. 18 It is recommended that these medications are avoided in women of childbearing potential. 19 In addition to major malformations, in utero exposure to valproate is associated with a significantly lower IQ at age 3 as compared with exposure to other AEDs (P¼.009). 20 Exposure to topiramate in the first trimester has been associated with a 10-fold increase in oral clefts as compared with the general population 18 and potentially an increased risk of hypospadias 21 and low birth weight. 22 At this time, there is insufficient experience with newer AEDs, such as lacosamide, perampanel, or eslicarbazepine, during pregnancy to determine the risk associated with these specific medications.
Minimizing the risk of complications from AED use during pregnancy requires preventive planning. Women with epilepsy should be given the lowest dose of the fewest AEDs needed to control seizures before pregnancy so as to decrease the risk of major congenital malformations. Folic acid supplementation before conception is recommended, though there is no consensus on the dose. If possible, AEDs with higher risks of malformations should be avoided, and if they are used, the choice needs to be a shared decision between the physician and the patient.
Elderly Patients
The incidence of epilepsy increases during adult years and, after age 60, is higher than that during the first year of life. 23 Because of medical comorbidities and changes in pharmacokinetic properties, treatment of epilepsy in elderly populations does require extra attention. Drug interactions and comorbid illnesses can result in increased sensitivity to adverse effects. Slower drug metabolism, decreased protein binding, and decreased renal clearance increase the risk of medication toxicity. 24 Clinical trials have shown that older patients can be seizure free on lower doses of AEDs than what would be used in the general adult epilepsy population. 25 The risk of adverse effects needs to be given particular consideration in the elderly population because of the prevalence of medical comorbidities. Antiepileptic drug selection should take care not to exacerbate preexisting conditions, such as cardiac arrhythmias, ataxia, or tremor. Long-term use of AEDs is associated with decreased bone density, increasing the risk of fracture in an at-risk population. The risk of osteoporosis in the new AEDs is not yet known, though it is thought that they may be safer because of lack of hepatic enzyme induction.
The Veterans Affairs cooperative trial on geriatric epilepsy compared gabapentin, lamotrigine, and carbamazepine in elderly patients with newly diagnosed epilepsy. Medication adherence was limited by adverse effects, with carbamazepine most commonly discontinued because of adverse effects. No one medication demonstrated superior seizure control. It was concluded that lamotrigine or gabapentin should be first-line treatment over carbamazepine, specifically because of tolerance. 26 Epilepsy is common in elderly adults and requires treatment to improve patient safety. Treatment does require consideration of coexistent medical conditions, concurrent medications, and recognition that changes in pharmacokinetics may mandate a lower AED dose to achieve therapeutic success.
CONSIDERATION OF COMORBIDITIES
Epilepsy as a disease often entails multiple symptoms beyond seizures. There is an increase in the incidence of mood disorders and neurocognitive effects. Management of these symptoms needs to be balanced against maintaining seizure control. Many AEDs also have benefit in other chronic conditions, such as neuropathic pain or migraine, and the coexistence of these conditions can influence AED selection (Table 5) .
Cognition is associated with epilepsy syndromes. For example, patients with juvenile myoclonic epilepsy typically have entirely normal cognition whereas those with LennoxGastaut syndrome have a static encephalopathy. Patients with focal epilepsy may have more discrete deficits that correlate with the seizure onset zone, for example, naming and verbal memory deficits in patients with mesial temporal epilepsy from the dominant hemisphere. Over time, poor seizure control can correlate with cognitive declines, and treatment of the underlying epilepsy is the most effective way to prevent the declines. After epilepsy surgery, seizure freedom may be associated with improved cognition. In patients with known epilepsy and cognitive decline, longterm electroencephalogram monitoring should be considered to rule out subclinical seizures as a cause. Antiepileptic drugs have the potential to negatively affect cognition. Higher doses of topiramate are associated with wordfinding difficulties and slowed cognition. Older adults have also been shown to be more susceptible to cognitive adverse effects of AEDs. 27 The incidence of depression is increased in patients with epilepsy compared with the general population. The prevalence of depression is 10% to 20% in patients with controlled epilepsy and 20% to 60% in patients with uncontrolled epilepsy. 28, 29 Depression can also be caused or exasperated by AEDs. Levetiracetam and phenobarbital are highly associated with adverse effects on mood. Additional AEDs that may adversely affect mood are perampanel, zonisamide, topiramate, gabapentin, vigabatrin, and tiagabine. Mood disorders need to be considered in AED selection (Figure) .
Antidepressants can safely be used in patients with epilepsy and depression. Although bupropion and some tricyclic antidepressants may lower seizure threshold, selective serotonin reuptake inhibitors such as citalopram, paroxetine, and sertraline are not likely to affect seizure control.
Both AEDs and underlying epilepsy contribute to these comorbid conditions. It is important to recognize these issues when caring for a patient with epilepsy, minimize possible contributions from AEDs, and manage, when possible, to improve quality of life.
Ideally, seizures are controlled by the appropriate AED chosen for an individual patient. However, once a patient fails to respond to an appropriate dose of an appropriate AED for their seizure type, the likelihood of seizure response decreases with each subsequent AED. Kwan and Brodie 30 reported that patients with an inadequate response to initial treatment were likely to have refractory epilepsy. The prospective study followed 525 patients treated at a single epilepsy center. Among patients who were previously untreated, 47% were seizure free when treated with the first AED, 13% were seizure free when the second drug was tried, and only 4% were seizure free when treated with a third AED or multiple AEDs. 30 These results have led to the recommendation that after trials of 2 appropriate AEDs, if a patient remains uncontrolled, they are considered medically refractory, and additional treatment options need to be considered. 
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EPILEPSY SURGERY
In patients with medically refractory epilepsy, surgery offers the greatest likelihood of seizure freedom if a single seizure focus can be identified and safely removed. Current imaging and neurophysiology technology allow for greater likelihood of localizing the seizure onset zone for resection.
The most common, and best studied, epilepsy surgery is anterior temporal lobectomy (ATL) for medically refractory temporal lobe epilepsy. Anterior temporal lobectomy has been shown to be superior to medical management in a randomized controlled trial. Eighty patients were randomly assigned to surgery or continued AED treatment for 1 year. At 1 year, 58% of patients in the surgery group were free of seizures with loss of awareness as compared with only 8% of patients in the medical management group. Patients in the surgical group had improved quality of life and trended toward higher rates of employment or school enrollment. 32 Nonrandomized studies with longer periods of follow-up have found sustained efficacy and quality of life improvements. In a prospective study following 89 patients after ATL, 70% were seizure free at 5 years. Neuropsychometric testing remained stable between baseline and 1 year after surgery and measures of depression and anxiety improved. 33 In patients with mesial temporal sclerosis undergoing epilepsy surgery, long-term follow-up revealed concrete quality of life gains, with improvement in driving and employment status and in their family and social relationships. At a mean follow-up of 7 years, 91% of patients reported being satisfied with surgery. 11 Patients with epileptogenic lesions can also have good seizure and quality of life outcomes with epilepsy surgery, even when the lesion is extratemporal. When a single lesion such as cavernous malformation, neurocysticercosis, low-grade glioma, or malformation of cortical development correlates with the seizure onset zone and can be completely resected, seizure freedom rates can meet or exceed what is expected with ATL. [34] [35] [36] [37] When a patient with intractable epilepsy has normal neuroimaging findings, epilepsy surgery can still be performed, but may require additional steps during the evaluation, and a lower likelihood of seizure freedom. A retrospective study reported outcome data on 44 patients with normal magnetic resonance imaging (MRI) findings, even when performed with a "seizure protocol" and reviewed by experienced neuroradiologists, who underwent ATL for intractable epilepsy. Sixty percent of these patients were free of disabling seizures at last follow-up. Absence of contralateral or extratemporal discharge, single photon-emission computed tomography coregistered to MRI correlating with the anterior temporal lobe, and concordant nonspecific MRI findings in the resected temporal lobe all correlated with good outcomes. 38 Intractable nonlesional extratemporal epilepsy is a greater challenge, as extensive testing and intracranial monitoring is required to identify the seizure onset zone. 85 patients with intractable extratemporal epilepsy were evaluated at a single center; a seizure focus was identified and resected in only 24. Nine (38%) had an excellent outcome after at least 10 years of follow-up. An additional 3 patients had rare disabling seizures, and 6 patients reported a worthwhile improvement. 39 Patients with intractable epilepsy and normal MRI findings can still benefit from epilepsy surgery, but require specialized testing and referral to an epilepsy center.
For patients with well-defined epileptogenic lesions, MRI-guided stereotactic laser interstitial thermal therapy (LiTT) offers a less invasive treatment option. In patients with intractable mesial temporal epilepsy, LiTT is a reasonable, less invasive option. Long-term data are not available at this time, but in a small series of 15 patients, 53% of patients were free of debilitating seizures at 1 year. 40 Although data are limited, it has been suggested that LiTT has fewer neurocognitive effects than does ATL. 41 Laser interstitial thermal therapy also offers a less invasive approach to deep epileptogenic lesions and is commonly used for surgical treatment of hypothalamic hamartomas. This offers potential for successful treatment of the associated epilepsy with decreased morbidity. 42 In patients with medically refractory epilepsy, surgery is the only currently available treatment with potential for a cure. Decisions about epilepsy surgery are complex, and these patients should be referred to epilepsy centers for further evaluation.
DIETARY THERAPY
The ketogenic diet has been used for the treatment of epilepsy since the 1920s, though primarily in the pediatric population, as a palliative treatment to reduce seizure burden. The ketogenic diet is a high-fat, low-carbohydrate diet used with the intent to put the body into a state of ketosis. The precise mechanism by which the diet improves seizure control is not fully understood, though animal studies suggest ketone bodies may exert an antiepileptic effect through action on GABA synthesis or glutamate release. Other potential mechanisms include mitochondrial function or the mechanistic target of rapamycin pathway. The classic ketogenic diet is a 4:1 ratio of fat/carbohydrates and protein. This extremely restrictive diet is difficult to maintain, particularly in adults, and is typically initiated in the inpatient hospital setting. 43 The low glycemic index and modified Atkins diets provide less restrictive alternatives. These diets are still high-fat, low-carbohydrate diets, but, as opposed to the ketogenic diet, there is no calorie or fluid calculation, weighing of foods, or fasting upon initiation. Seizure control has not been shown to correlate with the degree of ketosis, and so these better tolerated diets can still provide benefit. 43 In a review of published studies of the ketogenic diet or modified Atkins diet in adults, overall 32% of patients on the ketogenic diet and 29% of patients on the modified Atkins diet achieved more than 50% seizure reduction. A few patients had robust responses, with 9% of patients on the ketogenic diet and 5% of patients on the modified Atkins diet reporting more than 90% seizure reduction. Typically, response lasted only as long as the patients maintained the diet. 44 A larger observational study included 133 patients naive to dietary therapy. One hundred one patients with medically refractory epilepsy were prescribed the modified Atkins diet; 36% of these patients exhibited more than 50% seizure reduction at 3 months, with a relatively sustained response of 30% at 1 year and 21% at 4 years. 45 Dietary therapies are not benign. These diets carry the risk of hyperlipidemia and atherosclerosis, osteoporosis, nephrolithiasis, malnutrition, excessive weight loss, and severe constipation. Routine monitoring of urine ketones, liver enzymes, fasting lipid profiles, and vitamin D, selenium, zinc, and carnitine levels is required. Patients may also require periodic renal ultrasounds, electrocardiograms, carotid ultrasound, and bone density scans. Dietary therapies are contraindicated in patients with liver disease, pancreatitis, mitochondrial disease, porphyria, and pyruvate carboxylase deficiency. 45 
NEUROMODULATION
Neuromodulation as a treatment of epilepsy has made important gains in the past 20 years, with multiple devices now in development and available. These devices allow for an option beyond medication when epilepsy surgery is not possible. Neuromodulation does not offer a cure for epilepsy, as surgery has the potential to do, but can help to reduce the frequency and severity of seizures. For patients with multifocal or generalized epilepsy, or focal epilepsy arising from eloquent cortex, neuromodulation provides hope for more effective treatment when medically refractory (Table 6 ).
VAGUS NERVE STIMULATION
Vagus nerve stimulation was approved for the treatment of epilepsy in 1997. The vagus nerve stimulator is implanted in the chest and connected to the left vagus nerve in the neck. The device is then programmed to give intermittent stimulation, while the patient has the option to trigger additional stimulation. Surgery to implant the device is performed under general anesthesia and is typically an outpatient procedure. The battery lasts between 5 and 10 years, depending on settings.
The initial randomized trials included patients with focal epilepsy, exhibiting an approximately 30% to 35% response rate (>50% seizure reduction). In contrast to AEDs, the response rates increase over 12 to 18 months. Treatment was well tolerated, with the most common adverse effects being hoarseness and voice changes with stimulation. 46, 47 Further experience has shown efficacy in primary generalized epilepsy and Lennox-Gastaut syndrome. 48, 49 Vagus nerve stimulation is an appropriate option for those patients with medically refractory epilepsy of multiple types, particularly when surgical treatment is not an option.
Vagus nerve stimulation has recently been augmented with an additional featuredstimulation based on response to tachycardia. Tachycardia commonly occurs in association with simple partial and complex partial seizures, independent of physical activity, and can serve as a seizure detection method. The new device has an additional lead to monitor the heart rate. When a certain threshold for heart rate increase is achieved, an additional stimulation is delivered. Data are limited, though studies so far have shown reasonable sensitivity in seizure detection. 50, 51 The additional benefit that cardiac-based seizure detection offers is not known at this time.
TRIGEMINAL NERVE STIMULATION
Trigeminal nerve stimulation potentially has benefits over vagus nerve stimulation because it can be administered through an external device, without requiring implantation of the device. Trigeminal nerve stimulation is approved in Europe, Canada, and Australia, but is still investigational in the United States. The external pulse generator is attached to transcutaneous electrodes, which are placed over the ophthalmic branches of the trigeminal nerve. Patients typically apply the electrodes to receive cyclic stimulation for at least 12 h/d.
The double-blind randomized trial enrolled 50 patients with uncontrolled focal epilepsy. The response rate (>50% reduction in seizures) was 30.2%, but not significant compared with the active control group (P¼.31). Stimulation was fairly well tolerated, with adverse effects limited to anxiety, headache, and skin irritation. 52 Further research is needed to improve the response, but an external stimulation device would have appeal to many patients with medically refractory epilepsy.
RESPONSIVE NEUROSTIMULATION
Responsive neurostimulation (RNS) allows the real-time seizure detection and delivery of electrical stimulation to prevent further seizure propagation. This allows the treatment of intractable epilepsy, in which surgery is not an option because of either multifocal epilepsy or onset in eloquent cortex.
The device required placement by a neurosurgeon, with the neurostimulator implanted in the skull. The stimulator is connected to 2 leads containing 4 recording and stimulating electrodes on either a depth lead or a subdural strip. After placement, electrocorticography (ECoG) allows for individualization of seizure detection parameters. Stimulation is then given in response to detected seizures.
The pivotal clinical trial included 191 patients with intractable focal epilepsy who were implanted with RNS. There was a 12-week blinded period during which patients received As opposed to AEDs, treatment response to neuromodulation often improves over time, and so a 12-week trial does not inform what the ultimate response will be. The patients in the initial randomized trial were followed in an open label trial, during which there was continued seizure reduction. The median seizure reduction was 44% at 1 year and 53% at 2 years. Patients also had improved quality of life, which was maintained through year 5 of the study. There were no adverse effects on cognitive function or mood. 54, 55 In addition to treatment, RNS provides longterm ECoG data, which can lead to further treatment options for some patients. Of the 191 patients enrolled in the initial trial, 82 patients had bilateral mesial temporal electrode placement. In one-third of these patients, it took over 1 month to record independent bilateral onset seizures, and in 16% of the patients, after an average of 4.6 years of continuous ECoG, only unilateral onset seizures were recorded. Given the temporal limitation of traditional inpatient video electroencephalogram monitoring, the long-term data from RNS allow a better understanding of seizure onset and the potential for more definitive surgical treatments. 56 
DEEP BRAIN STIMULATION
There has been interest in deep brain stimulation (DBS) to treat epilepsy for several decades, with the anterior nucleus of the thalamus an attractive target as a core component of the Papez circuit. The implantation of DBS for epilepsy is similar to that for Parkinson disease or dyskinesia, with a pulse generator implanted in the chest and 2 depth electrodes inserted into deep structures in the brain. The generator is then programmed to give stimulation at regular intervals, as opposed to responsive stimulation.
A randomized trial was performed for stimulation of the anterior nuclei of the thalamus for epilepsy, enrolling 110 patients with medically refractory epilepsy. All patients had DBS implanted with leads in the bilateral anterior nuclei of the thalamus and were then randomized to either treatment or sham groups for 12 weeks. Similar to the RNS trial, both treatment and sham groups had a reduction in seizure frequency during the blinded portion of the study; there was a 40.4% seizure reduction in the treatment group and 14.5% reduction in the sham group. Response in the sham group was not maintained over the 12-week blinded period. Response did improve, however, during the open label portion of the trial, with a 56% median seizure reduction at 2 years. There was a difference in adverse events in the treatment group, with those patients more likely to report depression or memory difficulties. Other adverse events included asymptomatic intracranial hemorrhage, implant site pain or infection, and paresthesias. These events did not occur at a higher frequency in the treatment versus sham group. 57 Treatment response was sustained on long-term follow-up without additional adverse events. At 1 year, 41% of patients were considered responders (>50% reduction in seizure frequency). At 5 years, the responder rate increased to 68%. There was improvement in quality of life over the same time period. 58 Despite positive results in the trial for stimulation of the anterior nuclei of the thalamus for epilepsy, DBS is not currently FDA approved for epilepsy, though it has been approved in Europe. There is ongoing research to determine optimal targets and stimulation settings and develop responsive DBS.
CONCLUSION
For a patient diagnosed with epilepsy today, a wide range of treatment options are available. Navigating the wide range of options requires keeping in mind 2 major principles: the goal of treatment is no seizures and no adverse effects, and the treatment must be matched to the patient and their epilepsy. This requires understanding the underlying epilepsy etiology and seizure classification, comorbid conditions, and asking about potential adverse effects at all visits. When appropriate medication trials fail to control seizures, patients should be referred to an epilepsy center for further evaluation of respective surgery as a potential cure. If surgery cannot be performed, dietary and device therapies can help to improve seizure control.
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